Although pets can have positive effects on blood pressure, cholesterol levels and triglyceride levels, they can also have germs which can make humans sick, according to the Centers for Disease Control and Prevention (CDC).

The Committee for Medicinal Products for Human Use, an arm of the European Commission, has recommended Bristol-Myers Squibb's Opdivo for approval, subject to final review by the full commission.

The Food and Drug Administration (FDA) will fast-track a review of Eagle Pharmaceuticals’ Ryanodex drug to treat exertional heat stroke (EHS) following positive clinical trial data.

Dupixent (dupilumab), an injectable drug from Sanofi and Regeneron Pharmaceuticals Inc. used to treat moderate to severe atopic dermatitis (AD), has been approved by the Food and Drug Administration (FDA).

Eli Lilly and Co. and the William Sansum Diabetes Center have agreed to collaborate on a five-year research plan with the goal of bettering the lives Latino people affected by diabetes.

In the weeks leading up to the collapse of the American Health Care Act, health policy expert Joseph Antos warned Republicans to take their time and improve of some of the provisions in the bill.

AstraZeneca's Inebilizumab (formerly MEDI-551) has been granted orphan designation as a treatment for neuromyelitis optica spectrum disorder (NMOSD) by the European Medicines Agency (EMA).

The American Heart Association and the American Stroke Association have developed a new process that aims to cut the amount of time between a stroke and initial emergency care to maximize a patient's chance for recovery.

Cancer patients in the European Union (EU) are one step closer to a new treatment option for classical Hodgkin lymphoma (cHL).

Shionogi Inc. and Purdue Pharma LP will launch and commercialize Symproic, a medication used to treat opioid-induced constipation (OIC) for adults suffering from chronic non-cancer pain, in the United States as early as this summer.

Sanofi Genzyme has expanded its Multiple Myeloma Journey Partners Program, which uses storytelling to improve its multiple myeloma patients’ outcomes as they cope with the second most common blood cancer worldwide.

A new intravenous drug designed to treat a specific type of skin cancer has been approved for use in the United States, according to a March 23 announcement from its makers, Merck KGaA and Pfizer Inc.

Abbott Laboratories spin-off AbbVie Inc. has become one of only a handful of pharmaceutical companies to join a nationwide network sharing data about cutting-edge cancer treatments.

Bristol-Myers Squibb Co. is joining Foundation Medicine to use the company’s extensive genomic profiling and molecular information solutions to identify predictive biomarkers in patients in clinical trials that are analyzing Bristol-Myers Squibb’s cancer immunotherapies, Bristol-Myers Squibb said in a press release.

The European Commission (EC) has authorized Pfizer’s Xeljanz oral medication to treat moderate to severe rheumatoid arthritis, which affects nearly 3 million people in Europe.

The nominee to lead the Food and Drug Administration faced questions today over his business connections to health care and pharmaceutical companies and promised lawmakers he would be an "impartial and passionate advocate for public health."

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) are moving forward on an immuno-oncology clinical research collaboration study.

Phase 3 clinical trials, the typical final step before a drug gains Food and Drug Administration (FDA) approval, must last long enough to accurately gauge treatment results.

Zejula, an anti-cancer drug that inhibits the ability of tumor cells to self-repair, has been approved by the Food and Drug Administration (FDA) for sale in the United States after a clinical trial showed the drug works on a broader range of cancers.

Sufferers of rheumatoid arthritis and a range of other inflammatory disorders may soon be able to purchase a generic version of adalimumab, the active ingredient in the popular medicine Humira.